Vaginal drug components include sex steroid precursors of 13 mg or less per dose selected from groups such as dehidropiandrosterona, dehidropiandrosterona sulfate, androst-5-en-3b, 17b diol and 4-androst-3.17-diona. In addition, there is a prostaglandin, diluent. Or medically acceptable vehicles, selected from the tri groupPure or mixed glycerin of two -, or natural or semi synthetic saturated, unsaturated, unsaturated or hydrogenated fatty acids； butter； palm oil, palm bean, partially hydrogenated cottonseed and coconut oil and their triglyceride derivatives； hydrogenated fatty alcohols and esters； polyoxystearin； Reordered hydrogenated vegetable oils； a rich mixture of monkeysSayNatural vegetable oil derived triglycerides； triglycerides； cocoa butter； and combinations of the above precursor chemicals. Claim 3: vaginal embolism, characterized by the inclusion of sex steroid precursors selected from populations such as dehydroepiandrosterona, dehidropiandrosterona sulfate, androst-5-en-3b, 17b diol and 4-androston-3, 17-diona, And a pharmaceutically acceptable precursor chemical suitable for vaginal administration from three - --.Pure or mixed glycerin of two -, or natural or semi synthetic saturated, unsaturated, unsaturated or hydrogenated fatty acids； butter； palm oil, palm bean, partially hydrogenated cottonseed and coconut oil and their triglyceride derivatives； hydrogenated fatty alcohols and esters； polyoxystearin； Reordered hydrogenated vegetable oils； a rich mixture of monkeysSayTriglycerides derived from natural vegetable oil； triglycerides； cocoa butter； and combinations of the above precursor chemicals, in which the weight of sex steroid precursors does not exceed 13 mg. Claim 6: the third claim refers to vaginal embolism, which is characterized by embolization consisting of 3 to 13 mg of this sex steroid precursor.Una composición farmacéutica para administración intravaginal que comprende 13 miligramos o menos por dosis de un precursor de esteroides sex
